Buy Incyte Genomics, Inc. (INCY) and Pharmacyclics (PCYC) Into ASCO Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Baird Bullish on Pharmacyclics (PCYC) Following ASCO Abstracts
May 15, 2014 7:01 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) saying the ASCO abstracts firms up IImbruvica's competitive profile.
Skorney comments, "We believe concerns over the competitive landscape in CLL will be kept in check following last night's... More
